Along with finding that the tumor suppressor protein SIRT6 is inactive in around 30 percent of cases of pancreatic
ductal adenocarcinoma (PDAC), the team
identified the precise pathway by which SIRT6 suppresses PDAC development, a mechanism different from the way it suppresses colorectal cancer.
Work by University of Manchester scientists has explored what allows some cases of
Ductal Carcinoma in Situ (DCIS), a non-invasive form of breast cancer, to resist treatment and come back, as well as
identifying a potential new target to improve the effectiveness of radiotherapy.